Topic guide
Articles and reference material connected to this topic, organised for clear reading.
Reading path
Boehringer Ingelheim will apply Ochre Bio’s discovery platform to develop novel, first-in-class regenerative treatments for late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and othe…
Read guide →Sprout Pharmaceuticals is appealing a Complete Response Letter (CRL) sent by the FDA concerning the company’s re-submitted New Drug Application (NDA) for flibanserin, a once-daily treatment for the most common…
Read guide →Dabigatran etexilate, an oral direct thrombin inhibitor, does not require INR monitoring, dose adjustments, or food restrictions. The FDA Cardiovascular and Renal Drugs Advisory Committee voted 9 to 0 in favor…
Read guide →Linagliptin improved blood glucose levels either as monotherapy or combined with other type 2 diabetes drugs. Treating type 2 diabetes patients using Boehringer Ingelheim’s (BI) oral candidate, linagliptin, le…
Read guide →Qiagen today said it has received FDA approval to market its Therascreen EGFR test as a companion diagnostic to guide use of Boehringer Ingelheim’s newly approved Gilotrif™ (afatinib) for the first-line treatm…
Read guide →Boehringer Ingelheim will partner with Hanmi Pharmaceutical to develop and commercialize HM61713, a third- generation treatment for EGFR mutation-positive lung cancer, in most of the world, the companies said …
Read guide →Sanction for DPP-4 inhibitor follows FDA nod in May. Boehringer Ingelheim and Eli Lilly received marketing authorization from the EC for linagliptin 5 mg film-coated tablets for the treatment of adults with ty…
Read guide →Innovative buyout structured around success of Actimis’ leading asthma compound. Boehringer Ingelheim will acquire Actimis Pharmaceuticals through a structured buyout in which Boehringer Ingelheim will acquire…
Read guide →Patients already receiving once-daily Viramune can be switched immediately to extended-release tablet. FDA has approved a once-daily tablet formulation of Boehringer Ingelheim Pharmaceuticals’ Viramune® (nevir…
Read guide →Firm will get $60 million over the first three years to use its DART platform. Boehringer Ingelheim and MacroGenics inked a global agreement to discover, develop, and commercialize antibody-based therapeutics …
Read guide →Sanction is the first under firms’ global diabetes alliance for late-stage development. FDA has approved Boehringer Ingelheim and Eli Lilly’s linagliptin tablets for the treatment of type 2 diabetes alongside …
Read guide →Company advanced first jointly developed candidate into the clinic for neuropathic pain. Evotec is to receive €2 million, or roughly $2.46 million, from Boehringer Ingelheim with the advancement of a compound …
Read guide →